Natural-product-like spiroketals and fused bicyclic acetals as potential therapeutic agents for B-cell chronic lymphocytic leukaemia

ChemMedChem

Volumn 3, Issue 12, 2008, Pages 1922-1935

  Milroy, Lech Gustav ^a   Zinzalla, Giovanna ^a   Loiseau, François ^a   Qian, Zizheng ^a   Prencipe, Giuseppe ^a   Pepper, Chris ^b   Fegan, Chris ^b   Ley, Steven V ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; Drug design; Leukaemia; Natural products; Structure activity relationships

Indexed keywords

ACETAL DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE 3; FURAN DERIVATIVE; SPIRO COMPOUND; SPIROKETAL;

ARTICLE; CHEMISTRY; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; LD 50; METABOLISM; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

ACETALS; ANTINEOPLASTIC AGENTS; CASPASE 3; FURANS; HUMANS; LETHAL DOSE 50; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; SPIRO COMPOUNDS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 57549117631     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200800265     Document Type: Article

References (32)

1. R. L. Auer, J. Gribben, F. E. Cotter, Br. J. Haematol. 2007, 139, 635.
2. J. C. Byrd, S. Stilgenbauer, I. W. Flinn, Hematology 2004, 1, 163.
3. T. Robak, M. Kasznicki, Leukemia 2002, 16, 1015.
4. M. J. Keating, S. O'Brien, S. Lerner, C. Koller, M. Beran, L. E. Robertson, E. J. Freireich, E. Estey, H. Kantarjian, Blood 1998, 92, 1165.
5. V. A. Morrison, K. R. Rai, B. L. Peterson, J. E. Kolitz, L. Elias, F. R. Appelbaum, J. D. Hines, L. Shepherd, R. E. Martell, R. A. Larson, C. A. Schiffer, J. Clin. Oncol. 2001, 19, 3611.
6. P. Hillmen, A. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, C. Sirard, J. Mayer, J. Clin. Oncol. 2006, 24, 6511.
7. L. Alinari, R. Lapalombella, L. Andritsos, R. A. Baiocchi, T. S. Lin, J. C. Byrd, Oncogene 2007, 26, 3644.
8. S. Demko, J. Summers, P. Keegan, R. Pazdur, Oncologist 2008, 13, 167.
9. D. Catovsky, S. Richards, E. Matutes, D. Oscier, M. J. S. Dyer, R. F. Bezares, A. R. Pettitt, T. Hamblin, D. W. Milligan, J. A. Child, M. S. Hamilton, C. E. Dearden, A. G. Smith, A. G. Bosanquet, Z. Davis, V. Brito-Babapulle, M. Else, R. Wade, P. Hillmen, Lancet 2007, 370, 230.
10. B. F. Eichhorst, R. Busch, G. Hopfinger, R. Pasold, M. Hensel, C. Steinbrecher, S. Siehl, U. Jager, M. Bergmann, S. Stilgenbauer, C. Schweighofer, C. M. Wendtner, H. Dohner, G. Brittinger, B. Emmerich, M. Hallek, Blood 2006, 107, 885.
11. F. Bosch, A. Ferrer, N. Villamor, M. Gonzalez, J. Briones, E. Gonzalez-Barca, E. Abella, S. Gardella, L. Escoda, E. Perez-Ceballos, A. Asensi, M. J. Sayas, L. Font, A. Altes, A. Muntanola, P. Bertazzoni, M. Rozman, M. Aymerich, E. Gine, E. Montserrat, Clin. Cancer Res. 2008, 14, 155.
12. T. Robak, Cancer Treat. Rev. 2007, 33, 710.
13. G. Del Poeta, Cancer 2008, 112, 119.
14. C. Pepper, H. Lowe, C. Fegan, C. Thurieau, D. E. Thurston, J. A. Hartley, P. Delavault, Br. J. Cancer 2007, 97, 253;
15. C. Pepper, R. M. Hambly, C. D. Fegan, P. Delavault, D. E. Thurston, Cancer Res. 2004, 64, 6750.
16. K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, M. Andreeff, Blood 2006, 108, 993.
17. a) P. Dreger, E. Montserrat, Leukemia 2002, 16, 985;
18. b) J. C. Byrd, S. Stilgenbauer, I. W. Flinn, Hematology 2004, 1, 163.
19. G. Zinzalla, L.-G. Milroy, S. V. Ley, Org. Biomol. Chem. 2006, 4, 1977.
20. L.-G. Milroy, G. Zinzalla, G. Prencipe, P. Michel, S. V. Ley, M. Gunaratnam, M. Beltran, S. Neidle, Angew. Chem. 2007, 119, 2545;
21. Angew. Chem. Int. Ed. 2007, 46, 2493.
22. For an excellent review of spiroketal containing natural products, see: F. Perron, K. F. Albizati, Chem. Rev. 1989, 89, 1617;
23. For a review of spiroketal and fused bicyclic acetal containing natural products, see: H. Kiyota, Marine Natural Products, Springer, Berlin 2006, p. 65 (Topics in Heterocyclic Chemistry, No. 5).
24. M. Ball, M. J. Gaunt, D. F. Hook, A. S. Jessiman, S. Kawahara, P. Orsini, A. Scolaro, A. C. Talbot, H. R. Tanner, S. Yamanoi, S. V. Ley, Angew. Chem. 2005, 117, 5569;
25. Angew. Chem. Int. Ed. 2005, 44, 5433.
26. S. V. Ley, A. C. Humphries, H. Eick, R. Downham, A. R. Ross, R. J. Boyce, J. B. J. Pavey, J. Pietruszka, J. Chem. Soc. Perkin Trans. 1 1998, 3907.
27. S. S. Mitchell, D. Rhodes, F. D. Bushman, D. J. Faulkner, Org. Lett. 2000, 2, 1605.
28. 50 value is defined as the concentration at which each compound tested induced 50% cell death in the cell cultures as quantified by Annexin V positivity.
29. We propose a structural reassignment of spiroketal 10 originally reported in reference [17] based on fresh analytical data. Please refer to the Supporting Information for further discussion.
30. D. Gautam, D. N. Kumar, B. V. Rao, Tetrahedron: Asymmetry 2006, 17, 819.
31. Based on previously developed unpublished Ley group methdology. For an example of continuous flow hydrogenation of unsaturated systems, please see: S. Saaby, K. R. Knudsen, M. Ladlow, S. V. Ley, Chem. Commun. 2005, 2909.
32. C. J. Pepper, A. Thomas, T. Hoy, C. Fegan, P. Bentley, Br. J. Haematol. 2001, 114, 70.